Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies

Reuters

2025/08/13

Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies

Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 "Fierce 15" most promising biotechnology companies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559262194"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559262194\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559262194?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559262194","market":"nz","top_or_hot":-1,"title":"Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-13 04:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL5GBkmL:1","article_id":"2559262194","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559262194","pubTimestamp":1755029883,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Erasca Inc.公布了他们消除癌症的使命和创新的RAS/MAPK途径策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":0.9},"content_text":"Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n    \n\n        Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}